PL3288588T3 - Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki - Google Patents

Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki

Info

Publication number
PL3288588T3
PL3288588T3 PL15754041T PL15754041T PL3288588T3 PL 3288588 T3 PL3288588 T3 PL 3288588T3 PL 15754041 T PL15754041 T PL 15754041T PL 15754041 T PL15754041 T PL 15754041T PL 3288588 T3 PL3288588 T3 PL 3288588T3
Authority
PL
Poland
Prior art keywords
treatment
linking agents
collagen fibers
improved cross
corneal ectasia
Prior art date
Application number
PL15754041T
Other languages
English (en)
Inventor
Giovanni Cavallo
Edoardo Stagni
Marco BIONDI
Piero Biondi
Original Assignee
Sooft Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sooft Italia S.P.A. filed Critical Sooft Italia S.P.A.
Publication of PL3288588T3 publication Critical patent/PL3288588T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL15754041T 2015-04-29 2015-04-29 Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki PL3288588T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15754041.0A EP3288588B1 (en) 2015-04-29 2015-04-29 Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia
PCT/IT2015/000117 WO2016174688A1 (en) 2015-04-29 2015-04-29 Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia

Publications (1)

Publication Number Publication Date
PL3288588T3 true PL3288588T3 (pl) 2019-02-28

Family

ID=53969406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15754041T PL3288588T3 (pl) 2015-04-29 2015-04-29 Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki

Country Status (8)

Country Link
US (1) US10688196B2 (pl)
EP (1) EP3288588B1 (pl)
ES (1) ES2693254T3 (pl)
HU (1) HUE040373T2 (pl)
PL (1) PL3288588T3 (pl)
PT (1) PT3288588T (pl)
SI (1) SI3288588T1 (pl)
WO (1) WO2016174688A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
EP3288588B1 (en) 2015-04-29 2018-08-15 Sooft Italia Spa Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
FR3099045B1 (fr) * 2019-07-22 2021-07-30 Univ Jean Monnet Saint Etienne Procede de production d’une pluralite d’implants a partir d’une cornee humaine ou animale prealablement prelevee
WO2022194392A1 (en) * 2021-03-19 2022-09-22 Ligi Tecnologie Medicali S.R.L Ophthalmic preparations for photo-crosslinking reactions
CN115089732A (zh) * 2022-07-22 2022-09-23 复旦大学附属中山医院 用于增强角膜生物力学的光敏剂光黄素-环糊精包合物
IT202300027207A1 (it) * 2023-12-19 2025-06-19 Alfonso Anania Uso della fenitoina come nuovo strumento per il crosslincaggio del collagene oculare, composizioni oftalmiche che la contengono e relativi metodi di preparazione

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411115D0 (en) 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
DE60143514D1 (de) 2000-02-11 2011-01-05 Gen Hospital Corp Photochemische gewebeverbindung
WO2004058289A1 (en) 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20080015660A1 (en) 2006-07-13 2008-01-17 Priavision, Inc. Method And Apparatus For Photo-Chemical Oculoplasty/Keratoplasty
ITRM20070356A1 (it) 2007-06-26 2008-12-27 Sooft Italia Srl Soluzione oculare sterile monouso e suo procedimento di produzione per il cross linking corneale del cheratocono
US20090149923A1 (en) 2007-12-07 2009-06-11 21X Corporation Dba Priavision, Inc. Method for equi-dosed time fractionated pulsed uva irradiation of collagen/riboflavin mixtures for ocular structural augmentation
IT1393402B1 (it) 2008-08-28 2012-04-20 Sooft Italia Spa Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
EP2253321A1 (en) 2009-05-06 2010-11-24 Roberto Pinelli Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique
BRPI1001009A2 (pt) * 2010-03-26 2012-01-24 De Souza Lima Acacio Alves Jr composições micro e nanoestruturadas para aplicação ocular no tratamento de ceratocone
WO2016174101A1 (de) 2015-04-27 2016-11-03 Oelmez Ali Abformlöffel
EP3288588B1 (en) 2015-04-29 2018-08-15 Sooft Italia Spa Improved cross-linking agents of collagen fibers for the use in the treatment of corneal ectasia

Also Published As

Publication number Publication date
PT3288588T (pt) 2018-11-13
ES2693254T3 (es) 2018-12-10
WO2016174688A1 (en) 2016-11-03
SI3288588T1 (sl) 2018-12-31
EP3288588B1 (en) 2018-08-15
EP3288588A1 (en) 2018-03-07
HUE040373T2 (hu) 2019-03-28
US10688196B2 (en) 2020-06-23
US20180236100A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL248804A0 (en) A water-based preparation for the treatment of dry eye
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
SI3288588T1 (sl) Izboljšana sredstva za prečno povezovanje kolagenskih vlaken za uporabo pri zdravljenju kornealne ektazije
IL246791A0 (en) Compositions and methods for treating eye diseases
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
GB201522555D0 (en) Eye treatment system
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
EP3130620A4 (en) Silicone composition, silicone emulsion composition, and fiber treatment agent
PL3145511T3 (pl) Kompozycja do leczenia oka
IL252904A0 (en) Methods and factors for treating diseases
GB201503967D0 (en) Biocompatible implants for use in tendon therapy
IL246855A0 (en) Materials for use in the treatment of retinitis
ZA201804037B (en) Aminophosphinic derivatives for preventing and treating eye pain
SI3406258T1 (sl) Zdravilo za zdravljenje putike
SG11201710686PA (en) Hair treatment agent
GB201513299D0 (en) Therapeutic agents
SG11201901985XA (en) Keratin fiber treatment composition
PL3229780T3 (pl) Kompozycje okulistyczne do zastosowania w leczeniu zespołu suchego oka
SG11201706935PA (en) Polymer treatment agent
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu